8-K: Viking Therapeutics Announces Positive Phase 1 Results for Oral Weight Loss Drug VK2735

Viking Therapeutics reports successful Phase 1 trial results for its oral weight loss drug, VK2735, showing significant placebo-adjusted weight loss and good tolerability.

Summary

• Viking Therapeutics has announced positive results from its Phase 1 clinical trial of an oral tablet formulation of VK2735, a dual GLP-1/GIP receptor agonist.
• The trial showed that VK2735 led to dose-dependent reductions in mean body weight from baseline, with up to 5.3% reduction observed after 28 days.
• Compared to placebo, VK2735 resulted in placebo-adjusted mean weight loss of up to 3.3% after 28 days, and up to 3.6% at day 34, six days after the last dose.
• Up to 57% of subjects treated with VK2735 achieved at least 5% weight loss after 28 days, compared to 0% for placebo.
• The drug was found to be safe and well-tolerated, with most adverse events being mild or moderate and minimal gastrointestinal side effects.
• Viking plans to initiate a Phase 2 trial of oral VK2735 in obesity in the second half of 2024.

Sentiment

Score: 9

Explanation: The document presents very positive results from the Phase 1 trial, with strong efficacy and a good safety profile. The company's plans for a Phase 2 trial and the potential market opportunity contribute to a highly positive sentiment.

Positives

• VK2735 demonstrated significant weight loss compared to placebo.
• The drug showed a dose-dependent response in weight reduction.
• Weight loss was sustained even after the treatment period.
• A high percentage of subjects achieved clinically meaningful weight loss of 5% or more.
• The drug was well-tolerated with minimal gastrointestinal side effects.
• The safety profile was encouraging, with no serious adverse events reported.

Negatives

• Some subjects experienced mild nausea, although the overall rate was low.
• One subject reported diarrhea, but this was less frequent than in the placebo group.

Risks

• The Phase 1 results may not be replicated in larger Phase 2 trials.
• Regulatory approvals are not guaranteed and may be subject to delays.
• The company faces competition from other weight loss drugs in development.
• The success of the drug depends on the ability to scale up manufacturing and distribution.
• There are risks associated with the cost and timing of clinical trials.

Future Outlook

Viking plans to initiate a Phase 2 trial of oral VK2735 in patients with obesity in the second half of 2024, and they believe that longer treatment duration and potentially higher doses may result in additional weight loss.

Management Comments

• Brian Lian, Ph.D., chief executive officer of Viking, stated that the Phase 1 results highlight VK2735's promising early weight loss and tolerability profile when dosed as an oral tablet.
• Management believes that longer treatment duration, at potentially higher doses, may result in additional weight loss.
• Management is particularly pleased with the initial safety and tolerability data, which suggest a differentiated profile with minimal gastrointestinal-related side effects.
• Management believes that an oral agent with good tolerability could represent an attractive potential treatment option for patients with obesity.

Industry Context

The announcement is significant as it highlights the potential of oral GLP-1/GIP agonists in the treatment of obesity, a rapidly growing market. The results position Viking as a potential competitor to companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) in the weight loss drug space.

Comparison to Industry Standards

• The 3.3% placebo-adjusted weight loss at 28 days is competitive with early results from other GLP-1 based therapies.
• The 57% of patients achieving 5% weight loss is a strong result compared to other early stage trials.
• The low rates of GI side effects are a positive differentiator compared to some existing GLP-1 agonists, such as Ozempic and Wegovy, which are known to cause nausea and vomiting in some patients.
• Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist that has shown significant weight loss, and VK2735 is aiming to compete in this space with an oral formulation.
• The oral formulation of VK2735 is a potential advantage over injectable therapies, which could improve patient compliance and convenience.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results.
• Employees may be motivated by the progress of the company's lead drug candidate.
• Patients with obesity may benefit from a new, effective, and well-tolerated treatment option.
• The results could attract potential partners or investors.

Next Steps

• Viking plans to continue further dose escalation in the current Phase 1 study.
• The company plans to initiate a Phase 2 trial of oral VK2735 in patients with obesity in the second half of 2024.

Key Dates

Keywords

VK2735, weight loss, obesity, GLP-1, GIP, clinical trial, Phase 1, oral tablet, metabolic disorders, dual agonist